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Kidney Transplantation from a Donor Following Cardiac Death 
Supported with Extracorporeal Membrane Oxygenation
To expand the donor pool, organ donation after cardiac death (DCD) has emerged. However, 
kidneys from DCD donors have a period of long warm ischemia between cardiac arrest and 
the harvesting of the organs. Recently, we used extracorporeal membrane oxygenation 
(ECMO) to minimize ischemic injury during ´no touch´ periods in a Maastricht category II 
DCD donor and performed two successful kidney transplantations. The kidneys were 
procured from a 49-yr-old male donor. The warm ischemia time was 31 min, and the time 
of maintained circulation using ECMO was 7 hr 55 min. The cold ischemia time was 9 hr  
15 min. The kidneys were transplanted into two recipients and functioned immediately 
after reperfusion. The grafts showed excellent function at one and three months post-
transplantation; serum creatinine (SCr) levels were 1.0 mg/dL and 0.8 mg/dL and the 
estimated glomerular filtration rates (eGFR) were 63 mL/min/1.73 m
2 and 78 mL/min/1.73 m
2 
in the first recipient, and SCr levels were 1.1 mg/dL and 1.0 mg/dL and eGFR were 56 mL/
min/1.73 m
2 and 64 mL/min/1.73 m
2 in the second recipient. In conclusion, it is suggested 
that kidney transplantation from a category II DCD donor assisted by ECMO is a reasonable 
modality for expanding donor pool.
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INTRODUCTION
Kidney transplantation has become an effective means of treat-
ing end-stage renal disease (ESRD), but the shortage of eligible 
organs limits its clinical application and is now a major prob-
lem for transplantation worldwide. Despite a social/legal con-
sensus regarding brain death since February 2000 in Korea, the 
number of patients waiting for kidney transplantation contin-
ues growing dramatically, and the shortage of donation after 
brain death (DBD) still remains a major problem. Despite ac-
tive donor actions and attempts to increase living donors using 
extended criteria or exchange donors, the discrepancy between 
the number of available kidneys for transplantation and the 
number of patients awaiting transplantation has been widen-
ing. At the end of 2010, the Korean Organization Network for 
Organ Sharing (KONOS) national waiting list for kidney trans-
plantation was approaching 9,294 patients, whereas only 1,223 
kidney transplantations were performed in a year, including 
479 transplants from DBD donors in 2009 (1). The mean wait-
ing time for kidney transplantation from a deceased donor was 
1,299 days in Korea, varying on the degree of HLA mis-match-
ing and blood type (1). 
  To expand the donor pool, organ donation after cardiac death 
(DCD) has been recently started in many countries, including 
Korea (2-5). However, kidneys from DCD donors retain a long 
period of warm ischemia between the cardio-circulatory arrest 
of donors and cold preservation of the donated organs. The 
warm ischemic damage during this period might lead the grafts 
to primary non-function or delayed graft function. The suitabil-
ity of a donor’s organs for transplantation declines rapidly dur-
ing the warm ischemic condition after cardiac death. Transplan-
tation surgeons are reluctant to use organs rescued from cardi-
ac arrested donors due to the threat of primary graft non-func-
tion related to prolonged warm ischemia time. To prevent or 
minimize the warm ischemic damage on the donated organs, it 
is necessary to make the warm ischemic time very short or to 
perfuse oxygenated blood into the donor organ, even after car-
diac arrest, until organ procurement. Kidneys from DCD do-
nors require additional support during preservation to main-
tain tissue viability.
  Uncontrolled DCD donors are those who have had an unex-
pected cardiopulmonary arrest or for whom cardiopulmonary 
resuscitation has been unsuccessful (Maastricht I, II). The use 
of veno-arterial extracorporeal membrane oxygenation (ECMO) 
after cardiac arrest restores the flow of warm oxygenated blood 
during the interval between death and organ procurement. Lee JH, et al.  •  Cardiac Death and Extracorporeal Membrane Oxygenation
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ECMO, a proven technology that can provide the normal perfu-
sion of oxygenated blood into organs in the absence of cardiac 
activity, has the potential to maintain organ quality even after 
cessation of cardiac circulation in uncontrolled DCD donors. 
The use of ECMO after cardiac death in order to maintain suffi-
cient oxygenation of potential donor organs has been reported 
in several studies (6-9). Those protocols introduce ECMO sup-
port immediately after death declaration through arterial and 
venous catheters that are inserted before death is declared. 
ECMO improved outcomes in transplanted kidneys, livers, and 
pancreas from DCD donors because of improved organ perfu-
sion and oxygenation before organ recovery. By maintaining 
the flow of oxygenated blood to the organs to the moment of 
recovery and thereby reducing warm ischemic time, ECMO 
improved the viability of donor organ function in a way similar 
to organs recovered from a brain-dead donor with a beating 
heart. That improvement in recovered organs permitted an ex-
pansion of the potential organ donor pool by 33% (7).
  In the first case of its kind in Korea, we recently used ECMO 
to minimize ischemic injury during the ‘no touch’ periods of a 
Maastricht category II DCD donor and performed two success-
ful kidney transplantations from the donor. 
 
MATERIALS AND METHODS
Study design
We retrospectively reviewed the medical records of DCD donors 
and 2 kidney transplant recipients. Medical conditions of the 
donor and procedures that might be related during processing 
of organ donation were recorded. Pre- and post-transplantation 
medical conditions of the two recipients and their graft func-
tions were also monitored. Recipients’ serum creatinine (SCr) 
and body weight were measured on a daily basis until two weeks 
post-transplantation and were then measured weekly. We used 
the SCr and estimated glomerular filtration rate (eGFR) as a pa-
rameter of the donor’s kidney function before organ recovery 
and recipients’ graft function after transplantation. The donor’s 
eGFR and recipients’ eGFR at one and three months post-trans-
plantation were calculated with the 4-variable MDRD (Modifi-
cation of Diet in Renal Disease) formula of Levey et al. (10): 
eGFR (mL/min/1.73 m
3)  =  175 × SCr
-1.154 × (Age)
-0.203 × 0.742 (if 
female) × 1.212 (if African American). 
  The warm ischemia time was defined as the time between 
the cessation of cardio-circulatory activity and the initiation of 
ECMO support, and the cold ischemia time was defined as the 
time between aortic cross-clamp with cold perfusion in the do-
nor and kidney revascularization in the recipient. 
 
Donor management before and during organ preservation
Careful physical examination and history taking from the family 
were obtained. Vital signs, including blood pressure, pulse rate 
and rhythm, respiratory rate, and trans-cutaneous oxygen satu-
ration, were monitored. Either inotropics such as norepineph-
rine and dopamine were administrated to stabilize vital signs, 
and vasopressin was given to control diabetes insipidus. 
  An ECMO device was applied to minimize warm ischemic 
injury of the kidneys following declaration of cardiac death. Af-
ter initiation of ECMO, the donor was transported to the oper-
ating room, where organs were procured using techniques sim-
ilar to those for donation after brain death donors. As soon as 
the organs were perfused with cold preserved histidine-trypto-
phan-ketoglutarate (HTK) solution via a femoral arterial cathe-
ter used for ECMO, we clamped the donor’s descending aorta 
to enable the preservation solution to flow effectively into intra-
abdominal organs. After organ recovery from the donor, the 
kidneys were biopsied for frozen section.
Kidney allocation 
Kidneys were allocated by the KONOS according to the guide-
lines, referring to donor information such as age, human leuko-
cyte antigen (HLA), ABO blood type, history of hypertension 
and diabetes, cause of death, serum creatinine, urine output, 
and laboratory results for transmittable diseases. 
Immunosuppression
Immunosuppression consisted of tacrolimus, corticosteroids, 
and mycophenolate mofetil. Tacrolimus was given orally at a 
dose of 0.2 mg/kg/day, starting just before transplantation. With-
in a month after transplantation, the dose of the drug was indi-
vidually adjusted, with a goal trough blood level between 10 ng/ 
mL and 15 ng/mL. Target blood trough levels of tacrolimus were 
reduced to between 7 ng/mL and 10 ng/mL after one month 
post-transplantation. Methylprednisolone was injected at the 
following doses: 500 mg on the day of operation, and 250 mg, 
125 mg, and 60 mg on post-operative days 1, 2, and 3, respec-
tively. Prednisolone was given at an oral dose of 30 mg/day start-
ing on post-operative day 4, then slowly tapered to a maintenance 
dose of 10 mg/day. For both recipients, basilixumab 20 mg was 
given intravenously just prior to transplant and four days after 
transplantation. 
Transplantation surgery
The kidney transplantation was performed in the usual man-
ner. Both kidneys were transplanted to the right common iliac 
artery and vein. The ureters were implanted in bladders using 
Lich-Gregoir’s methods. The transplant surgical procedures 
were simultaneously performed by two experienced surgeons.
Ethics Statements
This single center retrospective study has been approved by in-
stitutional review board of Ajou University School of Medicine 
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donor gave their informed consent for organ donation after 
cardiac death before ECMO device application. The two recipi-
ents were fully informed about kidney transplantation using 
the kidneys from DCD donor and gave their written consents 
prior to surgery.
RESULTS
Cardiac death and organ recovery from the donor
A 49-yr-old male patient with a traumatic subdural hematoma 
following emergency craniotomy and temporal lobectomy was 
referred to our transplant center. Informed consent for organ 
donation was taken from the family. Medical or social history 
such as hypertension, diabetes, viral hepatitis, and drugs/alco-
hol consumption was negative. His vital signs, including blood 
pressure and pulse rate, were unstable. Even though the GCS 
(Glasgow coma scale) was 5, the clinical findings did not meet 
the criteria of brain death, because he had a self-respiratory 
drive and minor motor activity. On the 15th day after the crani-
al surgery, cardiac arrest occurred. Intensive cardiopulmonary 
resuscitation for 40 min turned out to be unsuccessful. The ECMO 
device started running at 31 min after declaration of cardiac 
death and was maintained for 7 hr 55 min until the organ was 
preserved with cold HTK solution. The cold ischemic times of 
each kidney were 9 hr 15 min and 9 hr 25 min until re-perfusion 
of the recipient’s blood into the kidney graft was established.
  His renal function was well preserved until cardiac arrest. The 
initial serum creatinine level and eGFR were 0.8 mg/dL and 109 
mL/min/1.73 m
2, respectively, with adequate urine amount. 
After cardiac arrest, those values deteriorated to 1.6 mg/dL and 
49 mL/min/1.73 m
2, respectively, with trivial urine output while 
the ECMO running. 
  Each kidney had one renal artery and one renal vein; the right 
kidney weighed 285.4 g, and the left kidney weighed 269.5 g. 
They were easily perfused with HTK preservation solution dur-
ing the bench procedure without an intra-parenchymal vascu-
lar resistance. Time zero biopsy for frozen section, done during 
a bench procedure immediately after organ recovery, revealed 
no glomerular abnormality but was suspicious for acute tubu-
lar necrosis without overt necrosis.
Recipient selection
The first recipient, a 59-yr-old female, had been on peritoneal 
dialysis for 20 yr. She had 4 HLA antigens mis-matched, and 
negative lymphocyte cross matching to the donor. She had no 
history of diabetes mellitus and was only on anti-hypertensives. 
Preoperative assessment showed no serologic evidence for viral 
infection such as HIV and hepatitis B and C. She had been wait-
ing for kidney transplantation for 1,596 days. 
  The second recipient, a 43-yr-old female, had been on hemo-
dialysis for 6 yr. She had hypertension and diabetes mellitus, 
controlled with oral hypoglycemic medication and insulin. Five 
HLA antigens were mis-matched, and lymphocyte cross match-
ing was negative to the donor. There was no serological evidence 
of HIV and hepatitis B and C. She had been waiting for kidney 
transplantation for 1,708 days. 
Graft kidney function after the transplantation
The kidney grafts functioned immediately after reperfusion and 
made urine. The first recipient had 250-400 mL/hr of urine out-
put immediately post-transplantation that was adequately main-
tained. The SCr level was 8.6 mg/dL immediately post-trans-
plantation and steadily decreased to 1.4 mg/dL at seven days 
after the transplantation. On the Doppler ultrasonography at 
seven days post-transplantation, the implanted kidney showed 
normal contour without evidence of perfusion defect and resis-
tive indices between 0.66 and 0.69. She was home on day 10 
post-transplantation. At a month post-transplantation, the re-
cipient’s 24-hr urine was collected for the amount of urine out-
put (1,870 mL), creatinine excretion (910.7 mg), proteinuria (0 
mg), and creatinine clearance calculation (62.0 mL/min/BSA). 
At one and three months post-transplantation, the SCr levels 
were 1.0 mg/dL and 0.8 mg/dL, and the eGFR were 63 mL/
min/1.73 m
2 and 78 mL/min/1.73 m
2, respectively. 
  The second recipient also had 250-500 mL/hr of urine output 
immediately post-transplantation that decreased to 30-40 mL/
hr three days post-transplantation. Restriction of water intake 
was required for the following two days until recovery from the 
oliguric phase, and the urine output increased to 1,700 mL/day 
on day 7 post-transplantation. The SCr level was 7.8 mg/dL im-
mediately post-transplantation and during the oliguric phase 
and then slowly decreased to 2.4 mg/dL on day 7 post-trans-
plantation. Doppler ultrasonography for the implanted kidney 
at day 7 post-transplantation showed normal ranges of resistive 
indices, between 0.61 and 0.68, without evidence of perfusion 
defect. At a month post-transplantation, the recipient’s 24-hr 
urine was also collected for the amount of urine output (2,750 
mL), creatinine excretion (962.5 mg), proteinuria (0 mg), and 
creatinine clearance calculation (56.2 mL/min/BSA). At one 
and three months post-transplantation, the SCr levels were 1.1 
mg/dL and 1.0 mg/dL, and the eGFR were 56 mL/min/1.73 m
2 
and 64 mL/min/1.73 m
2, respectively. 
 
DISCUSSION
DCD is now becoming an accepted medical practice in many 
countries following a period during which the procedure was 
practically abandoned because of poor results with organs 
transplanted from those donors. In Korea, organ transplanta-
tion from a DCD donor is now emerging, and the clinical out-
come of a DCD program has been recently reported in Korea 
(3). Outcomes after DCD kidney transplantation have been Lee JH, et al.  •  Cardiac Death and Extracorporeal Membrane Oxygenation
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previously described to be inferior to DBD kidney transplanta-
tion (11, 12), because DCD kidneys inevitably sustain a longer 
period of warm ischemia than DBD. The first international 
workshop on DCD donation in Maastricht in 1995 classified 
four categories in accordance with the length of the time period 
of warm ischemia (13). In particular, uncontrolled donors such 
as category I and II donors have a long warm ischemia time. 
  To reduce that damage, rapid cooling of the organs is indicat-
ed. In many centers, in-situ preservation (ISP) is the method of 
choice for uncontrolled DCD donors, Maastricht category I and 
II (14, 15). However, Snoeijs et al. (16) reported 23.3% of failure 
to kidney transplantation combined with technical complica-
tions of ISP, such as impossible catheter insertion, poor flush 
out, using a pediatric catheter, and catheter balloon rupture. A 
prolonged catheter insertion time is associated with poor trans-
plant outcome, which not only depends on the longer warm 
ischemia time but also on the quality of the arterial tract. 
  ECMO is a device that provides temporary circulation sup-
port and systemic oxygenation for patients with reversible respi-
ratory failure that cannot be adequately supported with conven-
tional mechanical ventilation and inotropic support (17), and it 
has been accepted in organ preservation methods for DCD do-
nors. Maintaining circulation before retrieval, continuously dur-
ing the preservation period, or for a short period to resuscitate 
the kidney appears to be advantageous compared to hypother-
mic techniques such as ISP. Furthermore, normothermic pres-
ervation techniques may be used as a method to protect against 
preservation and ischemia/reperfusion injury, resuscitate the 
kidney to instigate repair mechanisms, and also allow a com-
prehensive assessment of the kidney before it is transplanted. 
Objective kidney graft quality assessment is a prerequisite to 
safely expand the donor pool without compromising results. As-
sessment of kidney viability before transplantation may be par-
ticularly advantageous for extended criteria or DCD donor kid-
neys to prevent the transplantation of non-functioning kidneys. 
Normothermic perfusion could offer a more accurate and im-
mediate assessment of viability compared to hypothermic tech-
niques (18). 
  In Spain, there has been a long period of experience with the 
use of ECMO in category I and II DCD donors (9, 19, 20). Using 
that technique, the results of DCD kidney transplantation were 
equivalent to DBD transplantation, with 1-yr and 5-yr graft sur-
vival rates of 87.4% and 82.1%, respectively (21). In this study, 
the clinical course and graft function of two recipients were 
similar to those of kidney transplantation from DBD donors in 
our center (data not shown).    
  In Korea, organ allocation is controlled by a national trans-
plantation organization, called KONOS, rather than a regional 
organ procurement organization. Usually, the organ allocation 
is initiated after issuing the reports of the HLA typing of donors. 
An additional long period of time was required for evaluation of 
recipients’ medical status, including the result of lymphocyte 
cross-matching. For those reasons, we spent a long supported 
circulation time using ECMO and cold ischemia time after pro-
curement of kidneys. Under the present conditions, many po-
tential DCD donors, especially Maastricht category I and II un-
controlled donors, would be abandoned. To expand donor or-
gan pool, aggressive but careful clinical approaching was rec-
ommended for DCD donors even in Maastricht category II do-
nors (22). Fortunately, despite a long preparation time for organ 
allocation, evaluation of recipients, and lymphocyte cross-match-
ing, hemodynamic circulation supported with ECMO allowed 
the donated kidney to be well preserved and gave excellent graft 
function after transplantation in this case.
  In conclusion, our experience showed that kidney transplan-
tation from a category II DCD donor assisted by ECMO is a rea-
sonable modality for expanding the donor pool. ECMO assisted 
organ preservation of DCD donors could improve renal graft 
outcomes after transplantation.  
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